BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evaluating BAT8008,an antibody-drug conjugate (ADC) that targets Trop2. The multicenter,open-label Phase 1 clinical s...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evaluating BAT8010,an antibody-drug conjugate (ADC) that targets HER2. The multicenter, open-labelPhase 1 clinical st...
World’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
